Arabkhazaeli Ali, Vijverberg Susanne J H, van der Ent Cornelis K, Raaijmakers Jan A M, Maitland-van der Zee Anke H
a Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences (UIPS), Faculty of Science, Utrecht University , Utrecht , the Netherland.
b Departments of Pediatric Respiratory Medicine , Wilhelmina Children's Hospital, University Medical Centre Utrecht , Utrecht , the Netherlands.
J Asthma. 2016 Dec;53(10):1012-7. doi: 10.1080/02770903.2016.1185439. Epub 2016 May 17.
Severe asthma exacerbations are often treated with short courses of oral corticosteroids (OCS). This study assessed the incidence of OCS being prescribed in asthmatic children of various age groups and calculated their chances of receiving subsequent OCS prescriptions.
Longitudinal Dutch community pharmacy data of 2272 children who were regular users of asthma medication was analyzed retrospectively. Incidence rates for first, second and third prescriptions of OCS were calculated, stratified by age and sex. Probabilities of receiving first, second or third OCS prescriptions were assessed with Kaplan-Meier analysis.
Incidence rates for first OCS prescriptions were 4.5 for the 1(st) year of life per 100 person-years (100PY); 3.9 for the 2(nd); 4.6 for the 3(rd); 4.2 for the 4(th), and 4.7 for the 5(th) year of life per 100PY. This was relatively high compared to incidence rates for children between the ages of 6 and 11 (ranging between 2.2 per 100PY (age 9) and 3.7(age 11)). Incidence rates for second and third OCS prescriptions were very high: 78.2(95%CI: 45.0-123.7) and 241.2(95%CI: 81.2-583.4) per 100PY for infants, respectively. The chances of receiving a first OCS prescription was higher in males (P value < 0.01).
In the Netherlands, the incidence of OCS being prescribed to children being treated with asthma medication in early childhood is relatively high for first OCS prescriptions and extremely high for second and third OCS prescriptions compared to other ages. Furthermore, there is a high probability of receiving a further OCS prescription shortly after an OCS prescription.
重度哮喘发作通常采用短期口服糖皮质激素(OCS)治疗。本研究评估了不同年龄组哮喘儿童开具OCS的发生率,并计算了他们后续接受OCS处方的几率。
回顾性分析了2272名经常使用哮喘药物的荷兰儿童的纵向社区药房数据。计算了OCS首次、第二次和第三次处方的发生率,并按年龄和性别分层。采用Kaplan-Meier分析评估接受首次、第二次或第三次OCS处方的概率。
1岁儿童OCS首次处方的发生率为每100人年(100PY)4.5次;2岁为3.9次;3岁为4.6次;4岁为4.2次;5岁为4.7次。与6至11岁儿童的发生率相比相对较高(每100PY在2.2次(9岁)至3.7次(11岁)之间)。婴儿OCS第二次和第三次处方的发生率非常高:分别为每100PY 78.2次(95%CI:45.0 - 123.7)和241.2次(95%CI:81.2 - 583.4)。男性接受首次OCS处方的几率更高(P值<0.01)。
在荷兰,与其他年龄段相比,幼儿期接受哮喘药物治疗的儿童开具OCS的发生率,首次处方相对较高,第二次和第三次处方极高。此外,在开具OCS处方后不久,再次接受OCS处方的可能性很大。